Jennison Associates
REGN icon

Jennison Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Jennison Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-17,700
Closed -$6.86M – 660
2017
Q1 		$6.86M Hold
17,700
– – 0.01% 501
2016
Q4 		$6.5M Buy
+17,700
New +$6.73M 0.01% 500
2016
Q2 		– Sell
-18,600
Closed -$6.7M – 656
2016
Q1 		$6.7M Buy
+18,600
New +$7.66M 0.01% 478

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jennison Associates's REGN Position: Q1 2026 in Review

Jennison Associates opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 115,199 shares worth $89M. The stake represents 0.06% of the portfolio and ranks #147 among its holdings. This is a return to the name: Jennison Associates previously reported a position in REGN as recently as Q2 2024.

Jennison Associates first reported a position in REGN in Q2 2015 and has held it in 23 quarters since. The position peaked at $1.09B in Q4 2015. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Jennison Associates held 115,199 shares of Regeneron Pharmaceuticals worth $89M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Jennison Associates position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.06% of Jennison Associates's portfolio in Q1 2026, its #147 holding.
  • Jennison Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 23 quarters since.
  • Jennison Associates's Regeneron Pharmaceuticals position peaked at $1.09B in Q4 2015.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.